Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicenter, Open-label, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Prophylactic VGA039 in Adolescent and Adult Patients With Von Willebrand Disease (VIVID-6)

NCT07115004 is registered in ClinicalTrials.gov with Vega Therapeutics, Inc as lead sponsor.

NCT NCT07115004
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07115004 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicenter, Open-label, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Prophylactic VGA039 in Adolescent and Adult Patients With Von Willebrand Disease (VIVID-6)
Lead sponsor
Vega Therapeutics, Inc
Phase
Phase 3
Overall status
Recruiting
Start date
October 15, 2025
Completion date
October 31, 2028
Enrollment
60 (estimated)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

von willebrand disease (vwd)